Cardiovascular Consequences After an Episode of COVID 19 Clinical Trial
Official title:
The CardioPostCovid Study: Cardiovascular Consequences After COVID-19
| NCT number | NCT04452630 |
| Other study ID # | 2020-36 |
| Secondary ID | |
| Status | Recruiting |
| Phase | |
| First received | |
| Last updated | |
| Start date | June 23, 2020 |
| Est. completion date | November 30, 2021 |
The occurrence of cardiovascular complications in SARS-CoV-2 infections appears to be more
frequent than in other viral respiratory infections, probably due to a singular
pathophysiology of this coronavirus.
The lack of characterization of cardiovascular damages linked to Covid-19 could have medium
and long-term consequences on the prognosis of patients. This problematic could lead to a
second major public health problem linked to Covid-19 and it is therefore crucial to keep
monitoring and screening patients at risk.
In this context of emerging infectious diseases, of poorly characterized cardiovascular
damages during infection and of absence of data on the long-term evolution of the infection,
the investigators propose to carry out a prospective and observational cohort study focused
on the evaluation and the systematic cardiovascular follow up of patients who survived an
episode of Covid-19, regardless of their cardiovascular profiles.
| Status | Recruiting |
| Enrollment | 200 |
| Est. completion date | November 30, 2021 |
| Est. primary completion date | July 23, 2020 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 18 Years and older |
| Eligibility |
Inclusion Criteria: • All adults affiliated to social security attending the post-Covid follow-up consultation, having presented an episode of Covid-19 diagnosed by at least one positive nasopharyngeal RT-PCR test for SARS-Cov-2 and considered recovered. Exclusion Criteria: - Age <18 years old - Major under guardianship or curatorship - Absence of non-opposition |
| Country | Name | City | State |
|---|---|---|---|
| France | Assistance Publique Hôpitaux de Marseille | Marseille |
| Lead Sponsor | Collaborator |
|---|---|
| Assistance Publique Hopitaux De Marseille |
France,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Presence of at least one clinical, biological and/or imaging cardiovascular anomaly within 1 month of recovering | Describe clinical, biological and imaging cardiovascular data 1 month after recovery from an episode of Covid-19 | 1 month |